المؤلفون: Matsushita, Kensuke, Delmas, Clément, Marchandot, Benjamin, Roubille, François, Lamblin, Nicolas, Leurent, Guillaume, Levy, Bruno, Elbaz, Meyer, Champion, Sebastien, Lim, Pascal, Schneider, Francis, Khachab, Hadi, Carmona, Adrien, Trimaille, Antonin, Bourenne, Jeremy, Seronde, Marie‐france, Schurtz, Guillaume, Harbaoui, Brahim, Vanzetto, Gerald, Biendel, Caroline, Labbe, Vincent, Combaret, Nicolas, Mansourati, Jacques, Filippi, Emmanuelle, Maizel, Julien, Merdji, Hamid, Lattuca, Benoit, Gerbaud, Edouard, Bonnefoy, Eric, Puymirat, Etienne, Bonello, Laurent, Morel, Olivier

المساهمون: Nanomédecine Régénérative (NanoRegMed), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des Maladies Métaboliques et Casdiovasculaires (UPS/Inserm U1297 - I2MC), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiologie & médecine expérimentale du Cœur et des Muscles U 1046 (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier), Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 (RID-AGE), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Amiens-Picardie, Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Centre de recherche Cardio-Thoracique de Bordeaux Bordeaux (CRCTB), Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hôpitaux de Marseille (APHM), The study was sponsored by the Fédération Française de Cardiologie and was funded by unrestricted grants from Daiichi‐Sankyo and Maquet SAS. Complementary grants will be sought for dedicated research projects within the main study.

المصدر: ISSN: 2047-9980 ; Journal of the American Heart Association ; https://hal.science/hal-04474986Test ; Journal of the American Heart Association, 2024, 13 (5), pp.e030975. ⟨10.1161/JAHA.123.030975⟩.

مصطلحات موضوعية: cardiogenic shock, guideline‐directed medical therapy, heart failure, left ventricular ejection fraction, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.IB]Life Sciences [q-bio]/Bioengineering

الوصف: International audience ; Background The effects of pharmacological therapy on cardiogenic shock (CS) survivors have not been extensively studied. Thus, this study investigated the association between guideline‐directed heart failure (HF) medical therapy (GDMT) and one‐year survival rate in patients who are post‐CS. Methods and Results FRENSHOCK (French Observatory on the Management of Cardiogenic Shock in 2016) registry was a prospective multicenter observational survey, conducted in metropolitan French intensive care units and intensive cardiac care units. Of 772 patients, 535 patients were enrolled in the present analysis following the exclusion of 217 in‐hospital deaths and 20 patients with missing medical records. Patients with triple GDMT (beta‐blockers, renin‐angiotensin system inhibitors, and mineralocorticoid receptor antagonists) at discharge (n=112) were likely to have lower left ventricular ejection fraction on admission and at discharge compared with those without triple GDMT (n=423) (22% versus 28%, P <0.001 and 29% versus 37%, P <0.001, respectively). In the overall cohort, the one‐year mortality rate was 23%. Triple GDMT prescription was significantly associated with a lower one‐year all‐cause mortality compared with non‐triple GDMT (adjusted hazard ratio 0.44 [95% CI, 0.19–0.80]; P =0.007). Similarly, 2:1 propensity score matching and inverse probability treatment weighting based on the propensity score demonstrated a lower incidence of one‐year mortality in the triple GDMT group. As the number of HF drugs increased, a stepwise decrease in mortality was observed (log rank; P <0.001). Conclusions In survivors of CS, the one‐year mortality rate was significantly lower in those with triple GDMT. Therefore, this study suggests that intensive HF therapy should be considered in patients following CS.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/38390813; hal-04474986; https://hal.science/hal-04474986Test; https://hal.science/hal-04474986/documentTest; https://hal.science/hal-04474986/file/2024%20Matsushita%20et%20al.,%20Optimal%20Heart%2024p.pdfTest; PUBMED: 38390813

الإتاحة: https://doi.org/10.1161/JAHA.123.030975Test
https://hal.science/hal-04474986Test
https://hal.science/hal-04474986/documentTest
https://hal.science/hal-04474986/file/2024%20Matsushita%20et%20al.,%20Optimal%20Heart%2024p.pdfTest

المؤلفون: Matta, Anthony, Lhermusier, Thibault, Ohlmann, Patrick, Laszlo, Levai, Nader, Vanessa, Parada, Francisco Campelo, Elbaz, Meyer, Roncalli, Jerome, Carrié, Didier

المصدر: ESC Heart Failure; Jun2024, Vol. 11 Issue 3, p1452-1462, 11p

مصطلحات موضوعية: SURVIVAL rate, HEART diseases, CARDIAC patients, HEART valve prosthesis implantation, AORTIC valve transplantation, ACUTE kidney failure, CARDIAC pacemakers

مستخلص: Aims: There is a growing body of literature on long‐term outcomes post‐transcatheter aortic valve replacement (TAVR), but to our knowledge, few research have focused on patients with advanced cardiac dysfunction. This challenging category of patients was excluded from the Partner 3 clinical trial. There are no data to guide the choice of valve type in patients with severely depressed ejection fraction. This study evaluates the safety, efficacy, and outcomes of TAVR in patients with severe aortic stenosis and left ventricular ejection fraction (LVEF) ≤ 35%. It compares post‐TAVR survival outcomes with self‐expanding (SEV) versus balloon‐expandable (BEV) valves in the context of cardiac dysfunction. Methods and results: A retrospective cohort was conducted on 977 patients who underwent TAVR at Toulouse University Hospital between January 2016 and December 2020. The study population included two groups: LVEF ≤ 35% (N = 157) and LVEF ≥ 50% (N = 820). The group of LVEF ≤ 35% was divided into two subgroups according to the type of implanted device: self‐expanding (N = 66) versus balloon‐expandable (N = 91). The living status of each of study's participants was observed in December 2022. Patients with low ejection fraction were younger (82 vs. 84.6 years) and commonly males (71.3% vs. 45.6%). Procedural success was almost 98% in both study groups (97.5% vs. 97.9%). The prevalence of all in‐hospital post‐TAVR complications [acute kidney injury (3.8% vs. 2.2%), major bleeding events (2.5% vs. 3.2%), stroke (1.3% vs. 1.6%), pacemaker implantation (10.2% vs. 10.7%), major vascular complication (4.5% vs. 4.5%), new onset atrial fibrillation (3.2% vs. 3.4%), and in‐hospital death (3.2% vs. 2.8%)] were similar between groups (LVEF ≤ 35% vs. LVEF ≥ 50%). No difference in long‐term survival has been revealed over 3.4 years (P = 0.268). In patients with LVEF ≤ 35%, except for post‐TAVR mean aortic gradient (7.8 ± 4.2 vs. 10.2 ± 3.6), baseline and procedural characteristics were comparable between SEV versus BEV subgroups. An early improvement in LVEF (from 29.2 ± 5.5 to 37.4 ± 10.8) was observed. In patients with LVEF ≤ 35%, the all‐cause mortality rate was significantly higher in BEV than that in SEV subgroups, respectively (40.7% vs. 22.7%, P = 0.018). Kaplan–Meier curve showed better survival outcomes after SEV implantation (P = 0.032). A Cox regression identified BEV as independent predictor of mortality [HR = 3.276, 95% CI (1.520–7.060), P = 0.002]. Conclusions: In the setting of low LVEF, TAVR remains a safe and effective procedure not associated with an increased risk of complications and mortality. SEV implantation may likely result in superior survival outcomes in patients with advanced cardiac dysfunction. [ABSTRACT FROM AUTHOR]

: Copyright of ESC Heart Failure is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Kensuke Matsushita, Delmas, Clément, Marchandot, Benjamin, Roubille, François, Lamblin, Nicolas, Leurent, Guillaume, Levy, Bruno, Elbaz, Meyer, Champion, Sebastien, Lim, Pascal, Schneider, Francis, Khachab, Hadi, Carmona, Adrien, Trimaille, Antonin, Bourenne, Jeremy, Seronde, Marie-France, Schurtz, Guillaume, Harbaoui, Brahim, Vanzetto, Gerald, Biendel, Caroline

المصدر: Journal of the American Heart Association; 3/5/2024, Vol. 13 Issue 5, p1-14, 14p

المؤلفون: Matta, Anthony, G, Lhermusier, Thibault, Parada, Francisco, Campelo, Bouisset, Frederic, Canitrot, Ronan, Nader, Vanessa, Blanco, Stéphanie, Elbaz, Meyer, Roncalli, Jerome, Carrié, Didier

المساهمون: Holy-Spirit University of Kaslik Jounieh, Service Cardiologie CHU Toulouse, Pôle Cardiovasculaire et Métabolique CHU Toulouse, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Department of Psychiatry, Julius-Maximilians-Universität Würzburg (JMU)

المصدر: ISSN: 0896-4327.

مصطلحات موضوعية: MESH: Aged, 80 and over, MESH: Percutaneous Coronary Intervention, MESH: Retrospective Studies, MESH: Transcatheter Aortic Valve Replacement, MESH: Aortic Valve Stenosis / surgery, MESH: Coronary Artery Disease / therapy, MESH: Female, MESH: Fibrinolytic Agents / therapeutic use, MESH: Hemorrhage / epidemiology, MESH: Hospital Mortality, MESH: Humans, MESH: Male, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system

الوصف: International audience ; Introduction: The prevalence of coronary artery disease (CAD) detected in preoperative work-up for transcatheter aortic valve implantation (TAVI) is high. Instead, the management of a concomitant CAD remains unclear. We evaluate the impact of CAD and percutaneous coronary intervention (PCI) on TAVI procedures.Materials and methods: A retrospective study was conducted on 1336 consecutive patients who underwent TAVI in Toulouse University Hospital, Rangueil, France. The studied population was divided into 2 groups: CAD-TAVI group and No CAD-TAVI group. Then, the CAD-TAVI group was segregated into 2 subgroups: PCI-TAVI group and No PCI-TAVI group. In-hospital adverse clinical outcomes were assessed in each group.Results: Pre-TAVI work-up revealed significant CAD in 36% of 1030 patients eligible for inclusion in the study. The overall prevalence of in-hospital death, stroke, major or life-threatening bleeding, minor bleeding, major vascular complications, minor vascular complications, pacemaker implantation, and acute kidney injury was 2.7%, 2.4%, 2.8%, 3.6%, 3.9%, 7.5%, 12.5%, and 2.7%, respectively. Among the studied population, 55% were admitted to the cardiac care unit. No significant statistical difference was observed between groups. Discussion. CAD-TAVI population was not more likely to develop in-hospital adverse clinical outcomes post-TAVI procedure compared to others. Also, no significant difference regarding in-hospital death was observed. In parallel, performing PCI prior to TAVI did not increase the risk of in-hospital death and complications. The difference in terms of the distribution of antithrombotic regimen may explain the higher prevalence of bleeding events in the PCI-TAVI group.Conclusion: This study provides direct clinical relevance useful in daily practice. No negative impact has been attributed to the presence of a concomitant CAD and/or preoperative PCI on the TAVI hospitalization period.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33824628; hal-04511211; https://ut3-toulouseinp.hal.science/hal-04511211Test; https://ut3-toulouseinp.hal.science/hal-04511211/documentTest; https://ut3-toulouseinp.hal.science/hal-04511211/file/Matta_2021.pdfTest; PUBMED: 33824628; PUBMEDCENTRAL: PMC8016584

الإتاحة: https://doi.org/10.1155/2021/6672400Test
https://ut3-toulouseinp.hal.science/hal-04511211Test
https://ut3-toulouseinp.hal.science/hal-04511211/documentTest
https://ut3-toulouseinp.hal.science/hal-04511211/file/Matta_2021.pdfTest

المؤلفون: Matta, Anthony, Canitrot, Ronan, Nader, Vanessa, Bouisset, Frederic, Lhermusier, Thibault, Campelo-Parada, Francisco, Grunenwald, Etienne, Marcheix, Bertrand, Elbaz, Meyer, Carrie, Didier, Roncalli, Jerome

المساهمون: Institut Cardiomet CHU Toulouse, Pôle Cardiovasculaire et Métabolique CHU Toulouse, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Holy-Spirit University of Kaslik Jounieh, الجامعة اللبنانية بيروت = Lebanese University Beirut = Université libanaise Beyrouth (LU / ULB), Service Chirurgie Cardio-Vasculaire CHU Toulouse (CCV)

المصدر: ISSN: 0896-4327.

مصطلحات موضوعية: MESH: Aged, 80 and over, MESH: Retrospective Studies, MESH: Risk Factors, MESH: Transcatheter Aortic Valve Replacement* / adverse effects, MESH: Treatment Outcome, MESH: Aortic Valve / surgery, MESH: Aortic Valve Stenosis* / epidemiology, MESH: Aortic Valve Stenosis* / surgery, MESH: Female, MESH: Femoral Artery / surgery, MESH: Humans, MESH: Male, MESH: Prevalence, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system

الوصف: International audience ; Background: Vascular complications (VCs) are commonly observed after transfemoral transcatheter aortic valve implantation (TAVI) procedures. Closure devices for the access site were developed to reduce their incidence. We aim to evaluate the prevalence, predictors, and outcomes of the occurrence of post-TAVI VCs.Materials and methods: A retrospective study was conducted on 1336 consecutive patients who underwent TAVI at the University Hospital of Toulouse, France, between January 2016 and March 2020. All included procedures were performed through the common femoral artery, and ProGlide® was the used closure device. The studied population was divided into two groups depending on the occurrence of VCs defined according to Valve Academic Research Consortium-2 criteria.Results: The mean age of the studied population was 84.4 ± 6.9, and 48% were male. 90% of TAVI interventions were performed through the right femoral artery. The prevalence of VCs was 18.8%, and 3.7% were major. Prolonged procedure duration was an independent predictor of VCs. Using the right access site and smaller introducer size (14 Fr) were preventive factors. No significant difference in mortality rate was detected between the two groups.Conclusion: This study showed a low prevalence for post-TAVI VCs, especially for the major type. An increase in bleeding events and prolonged cardiac care unit stay were the common adverse outcomes.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/34729054; hal-04511195; https://ut3-toulouseinp.hal.science/hal-04511195Test; https://ut3-toulouseinp.hal.science/hal-04511195/documentTest; https://ut3-toulouseinp.hal.science/hal-04511195/file/Matta_2021.pdfTest; PUBMED: 34729054; PUBMEDCENTRAL: PMC8526196

الإتاحة: https://doi.org/10.1155/2021/5563486Test
https://ut3-toulouseinp.hal.science/hal-04511195Test
https://ut3-toulouseinp.hal.science/hal-04511195/documentTest
https://ut3-toulouseinp.hal.science/hal-04511195/file/Matta_2021.pdfTest

المؤلفون: Bonin, Mickael, Mewton, Nathan, Roubille, François, Morel, Olivier, Cayla, Guillaume, Angoulvant, Denis, Elbaz, Meyer, Claeys, Marc, Garcia-Dorado, David, Giraud, Céline, Rioufol, Gilles, Jossan, Claire, Ovize, Michel, Guerin, Patrice

المساهمون: Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes), Hôpital Cardiovasculaire Louis Pradel, Hospices Civils de Lyon (HCL), Physiologie & médecine expérimentale du Cœur et des Muscles U 1046 (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier), Université de Strasbourg (UNISTRA), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Université de Tours (UT), Service Cardiologie CHU Toulouse, Pôle Cardiovasculaire et Métabolique CHU Toulouse, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Universiteit Antwerpen = University of Antwerpen Antwerpen, Vall d'Hebron University Hospital Barcelona, Cardioprotection, Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)

المصدر: ISSN: 2047-9980 ; Journal of the American Heart Association ; https://hal.umontpellier.fr/hal-01797423Test ; Journal of the American Heart Association, 2018, 7 (4), pp.e006833. ⟨10.1161/JAHA.117.006833⟩.

مصطلحات موضوعية: pharmaceutical safety, ST‐segment elevation myocardial infarction, clinical, morphine, opioid, percutaneous coronary intervention, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system

الوصف: International audience ; Background: Morphine is commonly used to treat chest pain during myocardial infarction, but its effect on cardiovascular outcome has never been directly evaluated. The aim of this study was to examine the effect and safety of morphine in patients with acute anterior ST‐segment elevation myocardial infarction followed up for 1 year.Methods and Results: We used the database of the CIRCUS (Does Cyclosporine Improve Outcome in ST Elevation Myocardial Infarction Patients) trial, which included 969 patients with anterior ST‐segment elevation myocardial infarction, admitted for primary percutaneous coronary intervention. Two groups were defined according to use of morphine preceding coronary angiography. The composite primary outcome was the combined incidence of major adverse cardiovascular events, including cardiovascular death, heart failure, cardiogenic shock, myocardial infarction, unstable angina, and stroke during 1 year. A total of 554 (57.1%) patients received morphine at first medical contact. Both groups, with and without morphine treatment, were comparable with respect to demographic and periprocedural characteristics. There was no significant difference in major adverse cardiovascular events between patients who received morphine compared with those who did not (26.2% versus 22.0%, respectively; P=0.15). The all‐cause mortality was 5.3% in the morphine group versus 5.8% in the no‐morphine group (P=0.89). There was no difference between groups in infarct size as assessed by the creatine kinase peak after primary percutaneous coronary intervention (4023±118 versus 3903±149 IU/L; P=0.52).Conclusions: In anterior ST‐segment elevation myocardial infarction patients treated by primary percutaneous coronary intervention, morphine was used in half of patients during initial management and was not associated with a significant increase in major adverse cardiovascular events at 1 year.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/29440010; hal-01797423; https://hal.umontpellier.fr/hal-01797423Test; https://hal.umontpellier.fr/hal-01797423/documentTest; https://hal.umontpellier.fr/hal-01797423/file/2018%20Bonin%20et%20al.,%20Effect%20and%20safety.pdfTest; PUBMED: 29440010

الإتاحة: https://doi.org/10.1161/JAHA.117.006833Test
https://hal.umontpellier.fr/hal-01797423Test
https://hal.umontpellier.fr/hal-01797423/documentTest
https://hal.umontpellier.fr/hal-01797423/file/2018%20Bonin%20et%20al.,%20Effect%20and%20safety.pdfTest

المؤلفون: Delmas, Clement, Roubille, François, Lamblin, Nicolas, Bonello, Laurent, Leurent, Guillaume, Levy, Bruno, Elbaz, Meyer, Danchin, Nicolas, Champion, Sebastien, Lim, Pascal, Schneider, Francis, Cariou, Alain, Khachab, Hadi, Bourenne, Jeremy, Seronde, Marie‐France, Schurtz, Guillaume, Harbaoui, Brahim, Vanzetto, Gerald, Quentin, Charlotte, Delabranche, Xavier

المصدر: ESC Heart Failure; Feb2022, Vol. 9 Issue 1, p408-419, 12p

مصطلحات موضوعية: CARDIOGENIC shock, EPIDEMIOLOGY

مستخلص: Aims: Published data on cardiogenic shock (CS) are scarce and are mostly focused on small registries of selected populations. The aim of this study was to examine the current CS picture and define the independent correlates of 30 day mortality in a large non‐selected cohort. Methods and results: FRENSHOCK is a prospective multicentre observational survey conducted in metropolitan French intensive care units and intensive cardiac care units between April and October 2016. There were 772 patients enrolled (mean age 65.7 ± 14.9 years; 71.5% male). Of these patients, 280 (36.3%) had ischaemic CS. Organ replacement therapies (respiratory support, circulatory support or renal replacement therapy) were used in 58.3% of patients. Mortality at 30 days was 26.0% in the overall population (16.7% to 48.0% depending on the main cause and first place of admission). Multivariate analysis showed that six independent factors were associated with a higher 30 day mortality: age [per year, odds ratio (OR) 1.06, 95% confidence interval (CI): 1.04–1.08], diuretics (OR 1.74, 95% CI: 1.05–2.88), circulatory support (OR 1.92, 95% CI: 1.12–3.29), left ventricular ejection fraction <30% (OR 2.15, 95% CI: 1.40–3.29), norepinephrine (OR 2.55, 95% CI: 1.69–3.84), and renal replacement therapy (OR 2.72, 95% CI: 1.65–4‐49). Conclusions: Non‐ischaemic CS accounted for more than 60% of all cases of CS. CS is still associated with significant but variable short‐term mortality according to the cause and first place of admission, despite frequent use of haemodynamic support, and organ replacement therapies. [ABSTRACT FROM AUTHOR]

: Copyright of ESC Heart Failure is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Amar, Jacques, Lelouvier, Benjamin, Servant, Florence, Lluch, Jérôme, Burcelin, Rémy, Bongard, Vanina, Elbaz, Meyer

المصدر: Journal of the American Heart Association; 10/1/2019, Vol. 8 Issue 19, p1-11, 20p

المؤلفون: Orloff, Elisabeth, Fournier, Pauline, Bouisset, Frédéric, Moine, Thomas, Cournot, Maxime, Elbaz, Meyer, Carrié, Didier, Galinier, Michel, Lairez, Olivier, Cognet, Thomas

المصدر: Echocardiography; Sep2018, Vol. 35 Issue 9, p1300-1309, 10p

مصطلحات موضوعية: MYOCARDIUM physiology, MYOCARDIUM, DIAGNOSTIC imaging, CARDIAC patients, SPECTROPHOTOMETRY, SINGLE-photon emission computed tomography, CORONARY angiography, ANATOMY

مستخلص: Background: The aim of this study was to evaluate the value of multilayer strain analysis to the assessment of myocardial viability (MV) through the comparison of both speckle tracking echocardiography and single‐photon emission computed tomography (SPECT) imaging. We also intended to determine which segmental longitudinal strain (LS) cutoff value would be optimal to discriminate viable myocardium. Methods: We included 47 patients (average age: 61 ± 11 years) referred to our cardiac imaging center for MV evaluation. All patients underwent transthoracic echocardiography with measures of LS, SPECT, and coronary angiography. Results: In all, 799 segments were analyzed. We correlated myocardial tracer uptake by SPECT with sub‐endocardial, sub‐epicardial, and mid‐segmental LS values with r = .514 P < .0001, r = .501 P < .0001, and r = .520 P < .0001, respectively. The measurements of each layer strain (sub‐endocardial, sub‐epicardial, and mid) had the same performance to predict MV viability as defined by SPECT with areas under curve of 0.819 [0.778–0.861, P < .0001], 0.809 [0.764–0.854, P < .0001], and 0.817 [0.773–0.860, P < .0001], respectively. The receiver‐operating characteristic analysis yielded a cutoff value of −6.5% for mid‐segmental LS with a sensitivity of 76% and specificity of 76% to predict segmental MV as defined by SPECT. Conclusions: Multilayer strain analysis does not evaluate MV with more accuracy than standard segmental LS analysis. [ABSTRACT FROM AUTHOR]

: Copyright of Echocardiography is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Carrié, Didier, Lefevre, Thierry, Cherradi, Rhizlan, Dumas, Pierre, Elbaz, Meyer, Finet, Gérard, Puel, Jacques, Morice, Marie Claude

المساهمون: Service Cardiologie CHU Toulouse, Pôle Cardiovasculaire et Métabolique CHU Toulouse, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Institut Hospitalier J. Cartier, Hôpital Privé Jacques Cartier Massy, Hôpital Louis Pradel, Hôpital Louis Pradel CHU - HCL, Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL)

المصدر: ISSN: 0896-4327.

مصطلحات موضوعية: MESH: Coronary Angiography, MESH: Coronary Artery Disease, MESH: Tunica Intima, MESH: Ultrasonography, Interventional, MESH: Coronary Restenosis, MESH: Coronary Vessels, MESH: Female, MESH: Humans, MESH: Male, MESH: Middle Aged, MESH: Stents, MESH: Treatment Outcome

الوصف: International audience ; OBJECTIVES:To compare the volume of in-stent neointimal proliferation, assessed by intravascular ultrasound (IVUS), at 6-month follow-up after implantation of a coronary Carbofilm-coated stent (Tecnic Carbostent, Sorin Biomedica Cardio, Saluggia, Italy) versus a conventional 316 L stent (Rx Multi-Link Penta, Abbott Laboratories, Abbott Park, IL). BACKGROUND:Many trials suggest that stent characteristics and coating could be important determinants of restenosis. METHODS:From October 2004 to May 2005, 63 patients were randomized to Tecnic (T, n = 30) or Penta (P, n = 33). The primary end-point was in-stent volume of neointimal hyperplasia (NIH) measured by IVUS at 6 months. The secondary end-points included binary restenosis, minimal luminal diameter (MLD), target lesion revascularization, and major adverse cardiac events. RESULTS:There were no significant differences between T and P as to mean age, male gender, clinical status, complexity of the lesion, lesion length, reference vessel diameter before percutaneous coronary intervention (PCI), MLD pre-PCI, and stent-to-artery ratio. However, MLD poststenting was greater in P group than T group (2.81 +/- 0.45 mm vs. 2.49 +/- 0.33 mm, P < 0.002). At 6 months, angiographic late lumen loss (0.61 +/- 0.51 mm vs. 0.92 +/- 0.61 mm, P < 0.043), in-stent obstruction (25.86 +/- 16.48% vs. 38.33 +/- 19.56%, P = 0.021), and in-stent late loss volume (31.62 +/- 29.75 mm(3) vs. 57.28 +/- 37.16 mm(3), P = 0.016) were significantly lower in T group than in P group. CONCLUSION:Penta stent appears to offer a better deployment and a larger MLD post-PCI than Carbofilm-coated stent. However, a thicker NIH was observed on Penta stent at 6-month follow-up, when compared to Tecnic.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/17880335; inserm-00409564; https://inserm.hal.science/inserm-00409564Test; PUBMED: 17880335

الإتاحة: https://doi.org/10.1111/j.1540-8183.2007.00281.xTest
https://inserm.hal.science/inserm-00409564Test